Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Pocock, Rachael https://orcid.org/0000-0002-0051-1965
Farah, Nadine https://orcid.org/0000-0002-3945-9981
Richardson, Simon E. https://orcid.org/0000-0003-4343-4784
Mansour, Marc R. https://orcid.org/0000-0001-6835-3791
Abstract
Summary: T‐cell ALL (T‐ALL) is an aggressive malignancy of T‐cell progenitors. Although survival outcomes in T‐ALL have greatly improved over the past 50 years, relapsed and refractory cases remain extremely challenging to treat and those who cannot tolerate intensive treatment continue to have poor outcomes. Furthermore, T‐ALL has proven a more challenging immunotherapeutic target than B‐ALL. In this review we explore our expanding knowledge of the basic biology of T‐ALL and how this is paving the way for repurposing established treatments and the development of novel therapeutic approaches.
Description
Funder: Great Ormond Street Hospital Children's Charity
Funder: Blood Cancer UK Bennett Fellowship
Funder: Biomedical Research Council Fellowship
Keywords
Review, Reviews, leukaemia, novel treatments
Journal Title
British Journal of Haematology
Conference Name
Journal ISSN
0007-1048
1365-2141
1365-2141
Volume Title
Publisher
Publisher DOI
Sponsorship
Kay Kendall Leukaemia Fund (553577)
Cancer Research UK (C67279/A27957)
Wellcome Trust (203151/Z/16/Z)
Cancer Research UK (C67279/A27957)
Wellcome Trust (203151/Z/16/Z)